Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease
G S Polunin, S M Nurieva, D L Baiandin, N L Sheremet, L A Andreeva · 2000 · Vestn Oftalmol. 116(1):15–18
What does this source report?
Adjunctive treatment study reports changes in visual function in optic-nerve disease.
- Population and setting
- Three groups: two Semax administration routes and a control; sample size not established here
- Evidence type
- Clinical trial / comparison
- Preparation
- Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted
- Source language
- See original publication; indexed English metadata
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Background treatment complicates attribution.
- Allocation, blinding and numerical treatment effects require full-text review.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: G S Polunin, S M Nurieva, D L Baiandin, N L Sheremet, L A Andreeva. Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease Vestn Oftalmol. 116(1):15–18 2000.
Molekul research summary: https://molekul.io/research/ss-10741256. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry